ATE324902T1 - Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 - Google Patents

Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Info

Publication number
ATE324902T1
ATE324902T1 AT99958757T AT99958757T ATE324902T1 AT E324902 T1 ATE324902 T1 AT E324902T1 AT 99958757 T AT99958757 T AT 99958757T AT 99958757 T AT99958757 T AT 99958757T AT E324902 T1 ATE324902 T1 AT E324902T1
Authority
AT
Austria
Prior art keywords
orf virus
binds
activates
vegf receptor
growth factor
Prior art date
Application number
AT99958757T
Other languages
English (en)
Inventor
Lyn M Wise
Andrew A Mercer
Loreen J Savory
Stephen B Fleming
Steven A Stacker
Original Assignee
Ludwig Inst Cancer Res
Univ Otago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Univ Otago filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE324902T1 publication Critical patent/ATE324902T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99958757T 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 ATE324902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10668998P 1998-11-02 1998-11-02
US10680098P 1998-11-03 1998-11-03

Publications (1)

Publication Number Publication Date
ATE324902T1 true ATE324902T1 (de) 2006-06-15

Family

ID=26803915

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958757T ATE324902T1 (de) 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Country Status (8)

Country Link
US (2) US6541008B1 (de)
EP (1) EP1126863B1 (de)
JP (1) JP2003517275A (de)
AT (1) ATE324902T1 (de)
AU (1) AU775956B2 (de)
DE (1) DE69931178T8 (de)
NZ (1) NZ511119A (de)
WO (1) WO2000025805A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
DE60131146T2 (de) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
DE10122451A1 (de) * 2000-07-11 2002-04-04 Bayer Ag Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
LU90997B1 (en) * 2000-07-11 2003-01-08 Bayer Ag Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals ans anticancer pharmaceuticals
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
AU2002336837A1 (en) * 2001-11-01 2003-05-12 The University Of British Columbia Methods and apparatus for protein sequence analysis
WO2004045531A2 (en) * 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
CN100577205C (zh) * 2002-12-17 2010-01-06 艾库里斯有限及两合公司 绵羊副痘病毒的重组蛋白和由其制备的药物组合物
EP2351769A3 (de) * 2002-12-17 2011-11-02 AiCuris GmbH & Co. KG Rekombinante Proteine des Parapoxivirus Ovis und pharmazeutische Zusammensetzungen daraus
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
DK1660057T3 (da) 2003-08-27 2012-08-20 Ophthotech Corp Kombinationsterapi til behandling af neovaskulære øjenlidelser
JP2005110508A (ja) * 2003-10-02 2005-04-28 Nec Soft Ltd 血管内皮増殖因子受容体２型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
AU2013213745B2 (en) * 2005-10-06 2015-10-29 Trophogen, Inc. VEGF analogs and methods of use
US8114399B2 (en) 2006-05-17 2012-02-14 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
WO2010083495A2 (en) * 2009-01-18 2010-07-22 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
EP2431168B1 (de) 2010-09-20 2013-05-01 Bekaert Textiles N.V. Abdeckmaterial
AU2013263502B2 (en) * 2012-05-18 2018-02-08 Otago Innovation Limited Combination treatments and compositions for wound healing
PT2880164T (pt) 2012-07-30 2019-06-05 Trophogen Inc Superagonistas de ação prolongada de hormonas glicoproteicas
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
MX2016005973A (es) 2013-11-05 2016-11-14 Trophogen Inc Superagonistas de acción prolongada de la hormona de glicoproteína.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
SK120098A3 (en) * 1996-02-28 1999-03-12 Bayer Ag Parapoxviruses containing foreign dna, their production and their use in vaccines
BR9708401A (pt) * 1996-03-29 2000-01-04 Univ Otago Vetores de vìrus de para-varìola
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)

Also Published As

Publication number Publication date
DE69931178D1 (de) 2006-06-08
EP1126863B1 (de) 2006-05-03
EP1126863A4 (de) 2003-01-02
NZ511119A (en) 2004-04-30
US6541008B1 (en) 2003-04-01
WO2000025805A1 (en) 2000-05-11
EP1126863A1 (de) 2001-08-29
US20030211101A1 (en) 2003-11-13
AU775956B2 (en) 2004-08-19
WO2000025805A8 (en) 2000-08-31
JP2003517275A (ja) 2003-05-27
AU1605300A (en) 2000-05-22
DE69931178T2 (de) 2007-02-22
DE69931178T8 (de) 2007-06-28

Similar Documents

Publication Publication Date Title
ATE324902T1 (de) Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
CY1119512T1 (el) Αντισωματα του υποδοχεα 1 της ιντερφερονης αλφα και οι χρησεις αυτων
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
PT817648E (pt) Antagonistas do factor do crescimento de celulas endoteliais vasculares
DE60141409D1 (de) Homologe des nogo rezeptors
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
DE60040225D1 (en) Erythropoietin immunglobulin fusionsproteine
EA200301158A1 (ru) Антитела, блокирующие cripto, и их применения
ATE417058T1 (de) Derivate der z-domäne des proteins a von staphylococcus (spa), welche mit mindestens einer domäne des humanen faktors viii interagieren
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE363531T1 (de) Claudin polypeptide
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
ATE492266T1 (de) Farbverändernde mittel mit moringa extrakt
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
CY1110418T1 (el) Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
YU21292A (sh) Insekticidno efektivni peptidi
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
MX2023014037A (es) Proteinas de fusion activas renales y metodos de tratamiento que usan las mismas.
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties